OncoMatch/Clinical Trials/NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Is NCT07132515 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Enoxaparin, warfarrin, or apixaban for cirrhosis.
Treatment: Enoxaparin, warfarrin, or apixaban — We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Lab requirements
Blood counts
Platelets <10000 [excluded]
Kidney function
Createnine >1.9 [excluded]
Liver function
Child A & B
Platelets<10000, Createnine >1.9
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify